Illumina India Biotechnology Profile
Key Indicators
- Authorised Capital ₹ 13.00 Cr
- Paid Up Capital ₹ 4.99 Cr
- Company Age 6 Year, 8 Months
- Last Filing with ROC 31 Mar 2023
- Revenue Growth 316.12%
- Profit Growth 167.00%
- Ebitda 835.60%
- Net Worth 98.40%
- Total Assets 1383.53%
About Illumina India Biotechnology
Illumina India Biotechnology Private Limited (IIBPL) is a Private Limited Foreign Company Incorporated In India incorporated in India on 20 June 2018 (Six years and eight months 5 days old ). Its registered office is in Gurugram, Haryana, India.
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 13.00 Cr and a paid-up capital of Rs 4.99 Cr, as per Ministry of Corporate Affairs (MCA) records.
Frederic Mahieu, Jeyandran Chandrasekaran, and Suresh Gadamsetti serve as directors at the Company.
Company Details
- Location
Gurugram, Haryana, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media
Corporate Identity Details
- CIN/LLPIN
U51100HR2018FTC074675
- Company No.
074675
- Company Classification
Private Limited Foreign Company Incorporated In India
- Incorporation Date
20 Jun 2018
- Date of AGM
15 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Who are the key members and board of directors at Illumina India Biotechnology?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Frederic Mahieu  | Additional Director | Current | |
Jeyandran Chandrasekaran  | Additional Director | 12-Apr-2024 | Current |
| Suresh Gadamsetti | Director | 06-May-2024 | Current |
Financial Performance of Illumina India Biotechnology.
Illumina India Biotechnology Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 316.12% increase. The company also saw a substantial improvement in profitability, with a 167% increase in profit. The company's net worth Soared by an impressive increase of 98.4%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Illumina India Biotechnology?
In 2023, Illumina India Biotechnology had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Illumina India Biotechnology?
Illumina India Biotechnology has a workforce of 29 employees as of Mar 31, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Illumina India Biotechnology, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Illumina India Biotechnology's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
